In a sharp divergence from its pandemic-era highs, Moderna Incorporated finds itself trading at a substantial discount, even as it sharpens focus on a curated pipeline of mRNA-based therapies.
Esteemed India:: India Media Hub:: Indian Rummy:: Latest News:: Mid-Cap Stocks:: Sports Bazaar